Rein Therapeutics Q3 net loss narrows even as R&D spending rises
RNTX•Rein Therapeutics reported a Q3 net loss of $5.54 million, compared with $7.78 million a year earlier, as R&D spending rose. Preliminary blinded Phase 2 data showed 33% of patients had improved lung function at 12 weeks; the company expects RENEW topline data in 2027 and says cash should fund operations into Q1 2028.
1. Quarterly results
Rein Therapeutics reported a Q3 net loss of $5.54 million and a loss per basic share of $0.06. Operating expenses were $7 million, including higher R&D costs primarily for the Phase 2 RENEW trial of LTI-03.
2. Trial and cash outlook
Preliminary blinded Phase 2 data showed 33% of patients had improved lung function at 12 weeks. Preliminary blinded safety data showed no serious adverse events related to treatment and low discontinuation rates. The company said RENEW was 75% enrolled, expects topline data in 2027 and expects its current cash position to fund operations into Q1 2028.




